FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
American Uranium Reports Completed Drilling Strengthens Lo Herma Uranium Resource Upgrade for Upcoming Scoping Study